BMS Gains Second Indication For Krazati – One More Than Amgen’s Lumakras

CRC Added To NSCLC, Both Second-Line Or Later

 
• By Mandy Jackson
  
Approach to colon research using modern technologies
Krazati is the first KRAS G12C inhibitor approved in colorectal cancer • Source: Shutterstock

More from New Products

More from Scrip